[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mediterranean-diet\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mediterranean-diet":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,81,105,133,160,185],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100584218",false,"NCT06886477","Sickle Cell, Pain and Mediterranean Diet","Exploring the Mediterranean Diet as A Promising Approach for Alleviating Chronic Pain in Sickle Cell Disease","MedSCP","Inclusion Criteria:\n\n* Sickle Cell Disease Diagnosis\n* Chronic non-vaso-occlusive pain experienced on average ≥ 3 days per week for \\> 6 months (based on a response of \"Most days,\" \"Every day,\" or \"Some days\" and not \"Never\" to the question \"In the past 6 months, how often have you had pain?\")\n* Ability to speak, read, write, and understand English\n* A Mediterranean Eating Pattern for Americans (MEPA-III) score \\\u003C13, indicating that they do not follow a Mediterranean diet.\n\nExclusion Criteria:\n\n* Having taken systemic antimicrobials (to treat an infection in the previous 4 weeks)\n* History of colon cancer or inflammatory bowel disease (given potential untoward effects on the gut microbiome)\n* History of Clostridium difficile infection in the preceding 12 weeks; (4) unable to agree to maintain physical activity at the current level for the duration of the study\n* Currently following a Mediterranean diet, vegan diet, or dietary restrictions (e.g., religious, food intolerance\u002Fallergy) that preclude adoption of a Mediterranean diet\n* Lack of access to a space to safely store and reheat food items\n* Living in a facility that provides meals.\n* Pregnancy or breastfeeding\n* More than 7 in-patient hospital stays in the last year\n* Currently receiving dialysis treatment","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this study is to compare pain levels in individuals with Sickle Cell Disease while following the Mediterranean Diet to pain levels while following their usual diet.",[26,27,28,29],"Sickle Cell","Sickle Cell Disease","Sickle Cell Disease Without Crisis","Mediterranean Diet",[31,32,33,34,35],"sickle cell","sickle cell disease","sickle cell pain","diet","Mediterranean diet","RECRUITING","2026-04-01",{"date":39,"type":40},"2026-04-02","ACTUAL",{"date":42,"type":40},"2025-05-01",{"date":44,"type":20},"2026-12-31",{"name":46,"class":47},"University of Illinois at Chicago","OTHER",1,{"id":50,"slug":51,"hasResults":10,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100592090","energy2mob-study-obesity-management-in-bergued-100592090","NCT06988904","ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ","EFFECTIVENESS OF THE GROUP-BASED NUTRITION EDUCATION PROGRAMME FOR OBESITY MANAGEMENT IN BERGUEDÀ: A RANDOMISED CLINICAL TRIAL. ENERGY2MOB STUDY","ENERGY2MOB","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Overweight (BMI 27-30 kg\u002Fm²) or obesity (BMI 30-40 kg\u002Fm²)\n* Availability to attend at least 80% (6 out of 8) of the group sessions\n\nExclusion Criteria:\n\n* Significant language barriers (unable to communicate in Catalan or Spanish)\n* Previous bariatric surgery\n* Moderate to severe cognitive impairment\n* Severe psychiatric disorders preventing participation in group sessions","65 Years",{"count":59,"type":20},136,[23],"Background: Obesity is a prevalent multifactorial disease worldwide and has become a significant public health concern. The latest data from the 2022 Catalonia Health Survey show that 56.2% of men and 43.7% of women are overweight or obese, and 39% of children aged 6 to 12 years have excess weight. Excess adiposity poses a health risk as it is associated with various chronic diseases such as type 2 diabetes mellitus, hypertension, and dyslipidaemia, all of which affect quality of life and increase mortality risk.\n\nHypothesis: The Energy2MOB obesity management programme in Berguedà is a group-based intervention incorporating nutrition education and physical activity. It aims to reduce excess body weight and the risk of chronic diseases, including type 2 diabetes mellitus, dyslipidaemia, and hypertension, through a multicomponent approach that enhances dietary habits, physical activity, and emotional eating regulation.\n\nObjectives\n\n* Assess the effectiveness of the Energy2MOB programme in reducing body weight by 5-10% among adults with obesity in the Berguedà health region.\n* Measure lifestyle modifications, including dietary habits, physical activity, and emotional eating.\n\nMethodology: A randomised clinical trial with two groups (control and intervention) over one year, including individuals aged 18-65 years in the Berguedà health region with overweight grade II (BMI 27-30 kg\u002Fm²) or obesity (BMI 30-40 kg\u002Fm²). Exclusion criteria include significant language barriers, previous bariatric surgery, moderate to severe cognitive impairment, and severe psychiatric disorders preventing participation in sessions. Participants must attend at least 80% of the programme.\n\nMeasurements\n\n* Sociodemographic factors: sex, age, education level, marital status, employment status.\n* Lifestyle factors: alcohol and tobacco use, dietary habits, physical activity, emotional eating, health-related quality of life.\n* Anthropometric parameters: body weight, height, BMI, waist circumference.\n* Blood pressure, medication use, biochemical parameters (fasting glucose, glycated haemoglobin, lipid profile, liver and kidney function markers, C-reactive protein).\n\nStatistical Analysis: Accepting an alpha risk of 0.05 and a statistical power above 0.8 in a bilateral contrast, 68 subjects per group are required to detect a difference of at least 2.5 kg. A common standard deviation of 4.77 is assumed, with an estimated 15% dropout rate. Sample size calculations were performed using GRANMO version 8.0 (https:\u002F\u002Fwww.datarus.eu\u002Fca\u002Faplications\u002Fgranmo\u002F; consulted in November 2024).\n\nExpected Outcomes, Applicability, and Relevance: This study aims to generate scientific evidence on the effectiveness of multicomponent group-based interventions focused on improving nutrition, physical activity, and psychological well-being in obesity and chronic disease management. It seeks to create an environment that facilitates behavioural changes, leading to weight reduction and improved quality of life. The findings will also contribute to the development of a practical guide for addressing excess weight in primary healthcare settings.\n\nKeywords (maximum 6): Adult obesity, primary health care, group interventions, dietary interventions, multicomponent interventions, Mediterranean diet.",[29,63,64,65,66],"Overweight or Obese Adults","Exercise Therapy","Cardiovascular Diseases","Psychological Well Being",[68,69,35,70],"obesity and overweight","primary health care","dietary interventions","NOT_YET_RECRUITING","2025-05-22",{"date":74,"type":40},"2025-05-25",{"date":76,"type":20},"2025-06-07",{"date":78,"type":20},"2026-03-07",{"name":80,"class":47},"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina",{"id":82,"slug":83,"hasResults":10,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100589090","ketogenic-diet-therapy-in-patients-with-acromegaly-100589090","NCT06949891","KETOgenic Diet Therapy in Patients With ACROmegaly","Ketogenic Diet Therapy in Patients With Acromegaly","KETOACRO","Inclusion Criteria:\n\n* Male or female, 18 years or older\n* Diagnosis of acromegaly based on elevated GH and\u002For IGF-I levels due to a pituitary tumor\n* IGF-I levels above 80% upper limit of the normal range (xULN)) on a stable medication dose for at least 4 months\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Pegvisomant treatment\n* Has undergone pituitary surgery or radiotherapy within 6 months prior to s study entry;\n* It is anticipated that the patient will receive pituitary surgery or radiotherapy during the study;\n* History or presence of epilepsy;\n* Participation in a trail of an experimental drug or device within 30 days prior to screening;\n* Has a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study\n* Screening HbA1c \\> 6,5%;\n* Use of antidiabetic medication other than Metformin",{"count":90,"type":20},60,[23],"Acromegaly is caused by a tumour located at the base of the brain in the pituitary gland that produces too much growth hormone (GH). Symptoms caused by the excess of GH, and consequently increased insulin like growth factor 1 (IGF-1), are disproportionate growth of body parts, fluid retention, snoring and excessive perspiration. The various metabolic changes that occur due to acromegaly increase the risk for insulin resistance, diabetes mellitus, arterial hypertension, sleep apnoea and thus an increased risk of cardiovascular disease if left untreated. The result is signs and symptoms, increased mortality, morbidity, and greatly reduced quality of life (QoL). Normalisation of GH and IGF-1 gives a normalisation of mortality, however morbidity and QoL do not (completely) normalise. After surgery, a somatostatin analogue is the primary medical treatment, however, normalisation occurs in only 40% of patients.\n\nRecently, in a proof-of-principle study, the researchers showed that a 2-week ketogenic diet (low in carbohydrates) in patients with somatostatin analogues could significantly reduce IGF-1 values. Patients felt better and sometimes even needed less somatostatin analogues. This proof of concept led to the new hypothesis that acromegaly patients with somatostatin analogues should possibly be treated with a eucaloric low-carbohydrate ketogenic diet for a longer period of time to improve their biochemistry, symptoms and QoL. Additionally, this diet can make a significant contribution in the treatment of insulin resistance and glucose intolerance that often occur in this patient group.",[94,95,29],"Acromegaly Due to Pituitary Adenoma","Ketogenic Diet","2025-04-25",{"date":98,"type":40},"2025-04-29",{"date":100,"type":40},"2023-06-01",{"date":102,"type":20},"2028-05-01",{"name":104,"class":47},"Erasmus Medical Center",{"id":106,"slug":107,"hasResults":10,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":121,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":48},"100586242","gwas-to-identify-predictive-genetic-factors-for-the-success-of-dietary-intervention-in-the-treatment-of-ibs-symptoms-100586242","NCT06912828","GWAS to Identify Predictive Genetic Factors for the Success of Dietary Intervention in the Treatment of IBS Symptoms","Whole Genome Association Study (GWAS) to Identify Predictive Genetic Factors for the Success of Dietary Intervention in the Treatment of Irritable Bowel Syndrome (IBS) Symptoms","Inclusion Criteria:\n\n* Fulfillment of the Rome IV criteria for IBS\n* Provision of written informed consent.\n* Commitment of availability throughout the study period.\n* IBS-SSS \\> 175\n\nExclusion Criteria:\n\n* Any concomitant disease requiring specialized nutrition (e.g. renal failure, diabetes, celiac disease, cerebrovascular disease of the central nervous system, major surgical cavity).\n* Pregnancy.\n* Breastfeeding.",{"count":113,"type":20},100,"OBSERVATIONAL","This is a GWAS that aims to identify possible single nucleotide polymorphisms (SNPs) that are associated with the response in a combined dietary pattern low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols and Meditteranean diet (MED-LFD) in a small group of patients with Irritable Bowel Syndrome (IBS).",[117,118,119,29,120],"Irritable Bowel Syndrome (IBS)","Genome-wide Association Study","Single Nucleotide Polymorphisms","FODMAP Diet",[122,123],"diet response","nutrigenetics","2025-03-29",{"date":126,"type":40},"2025-04-06",{"date":128,"type":40},"2024-09-15",{"date":130,"type":20},"2027-02-15",{"name":132,"class":47},"Attikon Hospital",{"id":134,"slug":135,"hasResults":10,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":156,"leadSponsor":158,"locationsCount":48},"100574286","impact-of-mediterranean-diet-in-cardiovascular-risk-among-people-with-hiv-100574286","NCT06757309","Impact of Mediterranean Diet in Cardiovascular Risk Among People With HIV","Randomized Study to Evaluate the Impact of Dietary Optimization on Metabolic Profile, Immunoactivation and Cardiovascular Risk in HIV Population on ART","VIHMED","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Confirmed diagnosis of HIV infection.\n* On stable antiretroviral therapy (ART) with an undetectable viral load for at least 12 months.\n* LDL cholesterol levels \\>140 mg\u002FdL.\n* Low adherence to the Mediterranean diet, defined by a MEDAS score \\\u003C9.\n* Must be able to swallow tablets\n* Willingness and ability to provide informed consent.\n\nExclusion Criteria:\n\n* Use of lipid-lowering medications.\n* Chronic use of anti-inflammatory drugs.\n* Active hepatitis B or hepatitis C infection.\n* Other chronic inflammatory conditions (e.g., autoimmune diseases).\n* Familial hypercholesterolemia.\n* Uncontrolled metabolic conditions, such as hypothyroidism or diabetes mellitus.\n* Pregnancy or breastfeeding.\n* Cognitive or psychological conditions impairing the ability to comply with the study protocol.\n* Inability to provide informed consent.",{"count":142,"type":20},64,[23],"This study (VIHMET) aims to explore how dietary changes, specifically the adoption of a Mediterranean diet, can improve health outcomes in people living with HIV (PLWH) who are on antiretroviral therapy (ART). PLWH often experience chronic inflammation, metabolic disturbances, and elevated cardiovascular risk due to the virus, immune activation, and ART-related side effects. By examining dietary interventions, this study seeks strategies to reduce these risks and enhance quality of life.\n\nThe VIHMET study is a randomized clinical trial involving 64 participants at Hospital del Mar, Barcelona, randomized into control and intervention groups (1:2 ratio). The intervention group will receive personalized nutritional counseling to improve adherence to the Mediterranean diet, focusing on food selection and meal preparation. The control group will follow standard dietary recommendations. Assessments will occur at baseline, week 24, and week 48.\n\nKey health indicators include lipid profiles, markers of inflammation, immune activation, and cardiovascular health, assessed through non-invasive techniques like arterial stiffness and subclinical atherosclerosis measurements. Participants will complete questionnaires on diet adherence, physical activity, and quality of life, alongside anthropometric evaluations.\n\nEligible participants are adults with HIV, undetectable viral loads for 12+ months, and elevated LDL cholesterol with low Mediterranean diet adherence. Exclusion criteria include lipid-lowering drugs, chronic anti-inflammatory therapy, or other active inflammatory\u002Fmetabolic conditions.\n\nThis study aims to improve lipid levels, reduce inflammation, decrease arterial stiffness, and assess diet adherence's impact on quality of life and subclinical atherosclerosis. Results may inform dietary recommendations to reduce cardiovascular risks and enhance holistic care for PLWH.",[146,147,148,29],"HIV Infection","Inflammation","Cardiovascular Risk",[150,147,151],"HIV","Coronary Artery","2024-12-31",{"date":154,"type":40},"2025-01-03",{"date":152,"type":40},{"date":157,"type":20},"2026-07",{"name":159,"class":47},"Parc de Salut Mar",{"id":161,"slug":162,"hasResults":10,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":167,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":170,"briefSummary":171,"conditions":172,"keywords":175,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":48},"100480142","effectiveness-of-an-app-for-mobile-phones-e-12hr-to-increase-adherence-to-mediterranean-diet-in-university-students-100480142","NCT05532137","Effectiveness of an App for Mobile Phones (e-12HR) to Increase Adherence to Mediterranean Diet in University Students","Effectiveness of a Personalized Intervention Program for the Promotion of the Mediterranean Diet, Based on a Mobile Phone Application (e12HR), in Students of the University of Seville","Inclusion Criteria:\n\n* Both genders.\n* Over the age of 18.\n* Be a student at the Faculties of Medicine or Pharmacy (University of Seville).\n* Possess a mobile telephone with Internet access and iOS or Android operating system.\n\nExclusion Criteria:\n\n\\- Chronic pathologies, food intolerances or pregnancy (situations that could require specialized dietary recommendations).",true,{"count":169,"type":20},322,[23],"This is a controlled, randomized and multicentric clinical trial aimed at university students and performed at the Faculties of Medicine and Pharmacy at the University of Seville (Spain). Its objective is to evaluate the effect of an intervention based on the use of an information and communication technology (ICT) tool, specifically an application for mobile telephones (called e-12HR), in the improvement of adherence to the Mediterranean diet.",[29,173,174],"Diet Habits","Healthy Eating Index",[29,173,174],"2024-12-18",{"date":178,"type":40},"2024-12-24",{"date":180,"type":40},"2022-04-04",{"date":182,"type":20},"2025-12-16",{"name":184,"class":47},"Luis María Béjar Prado",{"id":186,"slug":187,"hasResults":10,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":167,"sex":16,"minAge":193,"maxAge":57,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100563411","intermittent-fasting-mediterranean-diet-and-nafld-100563411","NCT06615817","Intermittent Fasting, Mediterranean Diet and NAFLD","Comparison Between 14\u002F10 Intermittent Fasting and the Southern Italian Mediterranean Diet in the Variation of NAFLD Score, Inflammatory Indices and Intestinal Microbiota","RC2024-21","Inclusion Criteria:\n\n* Medium\u002Fsevere NAFLD (CAP\\>268)\n* BMI between 25 and 35\n\nExclusion Criteria:\n\n* diabetes treated with insulin,\n* fatty liver disease linked to alcohol consumption,\n* chronic inflammatory intestinal and oncological diseases,\n* visceral obesity which does not allow good resolution of Fibroscan images,\n* subjects in serious medical conditions that may compromise participation in the trial,\n* people following a special diet or unable to follow a diet for religious or other reasons.\n* Pregnancy and breastfeeding","30 Years",{"count":90,"type":20},[23],"This study aims to evaluate the effects of Intermittent Fasting (IF) 14\u002F10 compared with the Low Glycemic Index Mediterranean Diet on NAFLD.",[198,199,200,29],"NAFLD","Obesity","Intermittent Fasting",[199,202],"Liver Diseases","2024-10-22",{"date":205,"type":40},"2024-10-26",{"date":207,"type":20},"2025-01-01",{"date":209,"type":20},"2027-01-01",{"name":211,"class":47},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis"]